Cite
Pharmacodynamic and pharmacokinetic effects and safety of verinurad in combination with allopurinol in adults with gout: a phase IIa, open-label study.
MLA
Fleischmann, Roy, et al. “Pharmacodynamic and Pharmacokinetic Effects and Safety of Verinurad in Combination with Allopurinol in Adults with Gout: A Phase IIa, Open-Label Study.” RMD Open, vol. 4, Feb. 2018, pp. 1–9. EBSCOhost, https://doi.org/10.1136/rmdopen-2017-000584.
APA
Fleischmann, R., Winkle, P., Miner, J. N., Xiaohong Yan, Hicks, L., Valdez, S., Hall, J., Sha Liu, Zancong Shen, Gillen, M., & Hernandez-Illas, M. (2018). Pharmacodynamic and pharmacokinetic effects and safety of verinurad in combination with allopurinol in adults with gout: a phase IIa, open-label study. RMD Open, 4, 1–9. https://doi.org/10.1136/rmdopen-2017-000584
Chicago
Fleischmann, Roy, Peter Winkle, Jeffrey N. Miner, Xiaohong Yan, Liz Hicks, Shakti Valdez, Jesse Hall, et al. 2018. “Pharmacodynamic and Pharmacokinetic Effects and Safety of Verinurad in Combination with Allopurinol in Adults with Gout: A Phase IIa, Open-Label Study.” RMD Open 4 (February): 1–9. doi:10.1136/rmdopen-2017-000584.